179688-52-9

Basic information

• Product Name: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one
• Synonyms: 6-HYDROXY-7-METHOXY-3,4-DIHYDROQUINAZOLIN-4-ONE;6-Hydroxy-7-Methoxyquinazoline-4-One;6-hydydroxy-7-methoxyquinazoline-4-one;6-Hydroxy-7-methoxy-3H-quinazolin-4-one;7-METHOXYQUINAZOLINE-4,6-DIOL;4(3H)-Quinazolinone, 6-hydroxy-7-Methoxy-;Gefitinib interMediate III;6-Hydroxy-7-Methoxyquinazolin-4(1H)-one
• CAS NO: 179688-52-9
• Molecular Formula: C₉H₈N₂O₃
• Molecular Weight: 192.17
• EINECS: 1308068-626-2
• Product Categories: API intermediates
• Mol File: 179688-52-9.mol
• Article Data: 54

Chemical Properties

• Melting Point: 293 °C
• Boiling Point: 503.319 °C at 760 mmHg
• Flash Point: 258.198 °C
• Appearance: /
• Density: 1.478 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.659
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.39±0.20(Predicted)
• CAS DataBase Reference: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one(179688-52-9)
• EPA Substance Registry System: 6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one(179688-52-9)

Safety Data

• Hazardous Substances Data: 179688-52-9(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

6-Hydroxy-7-methoxy-4(1H)-quinazolinone is a reactant used in the preparation of 4-anilinoquinazoline derivatives that have shown antitumor activities. 6-Hydroxy-7-methoxy-4(1H)-quinazolinone was also used as a reactant in the synthetic preparation of 2-arylbenzothiazoles as kinase inhibitors.

InChI:InChI=1/C9H8N2O3/c1-14-8-3-6-5(2-7(8)12)9(13)11-4-10-6/h2-4,12H,1H3,(H,10,11,13)

Upstream product

• 31839-21-1 2-amino-5-hydroxy-4-methoxybenzoic acid 
• 3473-63-0 formamidine acetic acid 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 20357-25-9 6-nitroveratraldehyde 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 50413-44-0 methyl 2-amino-5-hydroxy-4-methoxybenzoate 
• 26791-93-5 methyl 4,5-dimethoxy-2-nitrobenzoate 
• 290-87-9 1,3,5-Triazine 
• 179688-53-0 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 
• 621-59-0 isovanillin 
• 64-18-6 formic acid 
• 77287-34-4 formamide 
• 57535-57-6 methyl 3-(benzyloxy)-4-methoxy-benzoate 

Downstream Products

• 179688-53-0 (4-hydroxy-7-methoxyquinazolin-6-yl) acetate 
• 179688-53-0 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 
• 295330-64-2 4-[(3-bromo-phenyl)amino]-6-methylcarbonyloxy-7-methoxy-quinazoline 
• 1389355-13-8 C₁₇H₁₄ClF₂N₃O₂ 
• 1389355-17-2 C₁₇H₁₅BrFN₃O₂ 
• 1389355-28-5 N-(3-chloro-4-fluorophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 1389355-29-6 N-(3-ethynylphenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 1389355-33-2 N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 295330-61-9 4-[(3-bromophenyl)amino]-6-hydroxy-7-methoxyquinazoline 
• 808762-62-1 4-((4-bromo-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate 
• 808762-63-2 4-((4-bromo-2-fluorophenyl)amino)-7-methoxyquinazolin-6-ol 
• 1437310-79-6 N-(4-bromo-2-fluorophenyl)-6-(3-chloropropoxy)-7-methoxyquinazolin-4-amine 
• 1438072-35-5 N-(4-bromo-2-fluorophenyl)-7-methoxy-6-(3-(tetrahydro-2H-[1,4]dioxino[2,3-c]pyrrol-6(3H)-yl)propoxy)quinazolin-4-amine 
• 1438080-43-3 tert-butyl 5-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate 

Relevant articles and documents

Studies leading to the identification of ZD1839 (Iressa): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.

Preparation method of high-purity gefitinib key intermediate

The invention belongs to the field of drug synthesis, and particularly relates to a preparation method of a high-purity gefitinib key intermediate 6-hydroxy-7-methoxy-3H-quinazoline-4-ketone. The synthesis method is simple to operate, the yield is high, t

INHIBITORS OF MUTANT EGFR FAMILY TYROSINE-KINASES

An epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitor comprising a functional group that can bind to the serine S797 residue in EGFR having a C797S mutation or the serine S805 residue in HER2 having a C805S mutation.